Peringatan Keamanan

LD50=4 gm/kg (orally in mice); LD50=3650 mg/kg (orally in rabbits)

Aminosalicylic acid

DB00233

small molecule approved

Deskripsi

An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.

Struktur Molekul 2D

Berat 153.1354
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

453 Data
Ammonium chloride The serum concentration of Aminosalicylic acid can be increased when it is combined with Ammonium chloride.
Ginkgo biloba The risk or severity of bleeding can be increased when Ginkgo biloba is combined with Aminosalicylic acid.
Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Aminosalicylic acid.
Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Aminosalicylic acid.
Probenecid The therapeutic efficacy of Probenecid can be decreased when used in combination with Aminosalicylic acid.
Treprostinil The risk or severity of bleeding can be increased when Treprostinil is combined with Aminosalicylic acid.
Prilocaine The risk or severity of methemoglobinemia can be increased when Aminosalicylic acid is combined with Prilocaine.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aminosalicylic acid.
Ketoprofen The risk or severity of bleeding and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Ketoprofen.
Dexketoprofen The risk or severity of bleeding and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Dexketoprofen.
Dicoumarol Aminosalicylic acid may increase the anticoagulant activities of Dicoumarol.
Phenindione Aminosalicylic acid may increase the anticoagulant activities of Phenindione.
Warfarin Aminosalicylic acid may increase the anticoagulant activities of Warfarin.
Phenprocoumon Aminosalicylic acid may increase the anticoagulant activities of Phenprocoumon.
Acenocoumarol Aminosalicylic acid may increase the anticoagulant activities of Acenocoumarol.
4-hydroxycoumarin Aminosalicylic acid may increase the anticoagulant activities of 4-hydroxycoumarin.
Coumarin Aminosalicylic acid may increase the anticoagulant activities of Coumarin.
(R)-warfarin Aminosalicylic acid may increase the anticoagulant activities of (R)-warfarin.
Ethyl biscoumacetate Aminosalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
Fluindione Aminosalicylic acid may increase the anticoagulant activities of Fluindione.
Clorindione Aminosalicylic acid may increase the anticoagulant activities of Clorindione.
Diphenadione Aminosalicylic acid may increase the anticoagulant activities of Diphenadione.
Tioclomarol Aminosalicylic acid may increase the anticoagulant activities of Tioclomarol.
(S)-Warfarin Aminosalicylic acid may increase the anticoagulant activities of (S)-Warfarin.
Digoxin The serum concentration of Digoxin can be decreased when it is combined with Aminosalicylic acid.
Acetyldigitoxin The serum concentration of Acetyldigitoxin can be decreased when it is combined with Aminosalicylic acid.
Deslanoside The serum concentration of Deslanoside can be decreased when it is combined with Aminosalicylic acid.
Ouabain The serum concentration of Ouabain can be decreased when it is combined with Aminosalicylic acid.
Digitoxin The serum concentration of Digitoxin can be decreased when it is combined with Aminosalicylic acid.
Oleandrin The serum concentration of Oleandrin can be decreased when it is combined with Aminosalicylic acid.
Cymarin The serum concentration of Cymarin can be decreased when it is combined with Aminosalicylic acid.
Proscillaridin The serum concentration of Proscillaridin can be decreased when it is combined with Aminosalicylic acid.
Metildigoxin The serum concentration of Metildigoxin can be decreased when it is combined with Aminosalicylic acid.
Lanatoside C The serum concentration of Lanatoside C can be decreased when it is combined with Aminosalicylic acid.
Gitoformate The serum concentration of Gitoformate can be decreased when it is combined with Aminosalicylic acid.
Acetyldigoxin The serum concentration of Acetyldigoxin can be decreased when it is combined with Aminosalicylic acid.
Peruvoside The serum concentration of Peruvoside can be decreased when it is combined with Aminosalicylic acid.
Dapsone The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Aminosalicylic acid.
Tioguanine The metabolism of Tioguanine can be decreased when combined with Aminosalicylic acid.
Azathioprine The metabolism of Azathioprine can be decreased when combined with Aminosalicylic acid.
Mercaptopurine The metabolism of Mercaptopurine can be decreased when combined with Aminosalicylic acid.
Lepirudin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Lepirudin.
Bivalirudin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Bivalirudin.
Alteplase The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Alteplase.
Urokinase The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Urokinase.
Reteplase The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Reteplase.
Anistreplase The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Anistreplase.
Tenecteplase The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Tenecteplase.
Abciximab The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Abciximab.
Drotrecogin alfa The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Drotrecogin alfa.
Streptokinase The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Streptokinase.
Argatroban The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Argatroban.
Ardeparin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ardeparin.
Fondaparinux The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Fondaparinux.
Pentosan polysulfate The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Pentosan polysulfate.
Dipyridamole The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dipyridamole.
Heparin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Heparin.
Enoxaparin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Enoxaparin.
Epoprostenol The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Epoprostenol.
Ximelagatran The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ximelagatran.
Desmoteplase The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Desmoteplase.
Defibrotide The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Defibrotide.
Ancrod The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ancrod.
Beraprost The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Beraprost.
Prasugrel The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Prasugrel.
Rivaroxaban The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Rivaroxaban.
Sulodexide The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Sulodexide.
Semuloparin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Semuloparin.
Idraparinux The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Idraparinux.
Cangrelor The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Cangrelor.
Astaxanthin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Astaxanthin.
Apixaban The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Apixaban.
Otamixaban The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Otamixaban.
Amediplase The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Amediplase.
Dabigatran etexilate The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dabigatran etexilate.
Danaparoid The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Danaparoid.
Dalteparin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dalteparin.
Tinzaparin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Tinzaparin.
Nadroparin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Nadroparin.
Triflusal The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Triflusal.
Ticagrelor The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ticagrelor.
Ditazole The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ditazole.
Vorapaxar The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Vorapaxar.
Edoxaban The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Edoxaban.
Sodium citrate The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Sodium citrate.
Dextran The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dextran.
Bemiparin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Bemiparin.
Parnaparin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Parnaparin.
Desirudin The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Desirudin.
Antithrombin Alfa The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Antithrombin Alfa.
Protein C The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Protein C.
Antithrombin III human The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Antithrombin III human.
Letaxaban The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Letaxaban.
Darexaban The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Darexaban.
Betrixaban The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Betrixaban.
Nafamostat The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Nafamostat.
Monteplase The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Monteplase.
Gabexate The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Gabexate.
Protein S human The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Protein S human.
Brinase The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Brinase.

Target Protein

Prostaglandin G/H synthase 1 PTGS1
Dihydrofolate reductase DHFR
Prostaglandin G/H synthase 2 PTGS2
Inhibitor of nuclear factor kappa-B kinase subunit alpha CHUK
Polyunsaturated fatty acid 5-lipoxygenase ALOX5
Group IIE secretory phospholipase A2 PLA2G2E

Referensi & Sumber

Synthesis reference: Thomas M. Parkinson, Joseph P. Brown, Robert E. Wingard, Jr., "Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract." U.S. Patent US4298595, issued January, 1975.

Contoh Produk & Brand

Produk: 3 • International brands: 3
Produk
  • Granupas
    Granule, delayed release • 4 g • Oral • EU • Approved
  • Nemasol Sodium Tab 500mg
    Tablet • 500 mg • Oral • Canada • Approved
  • Paser
    Granule, delayed release • 4 g/1 • Oral • US • Generic • Approved
International Brands
  • Pamisyl — Parke-Davis
  • Rexipas — Bristol-Myers Squibb
  • Rezipas — Bristol-Myers Squibb

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul